title: The Cryolife-O'Brien stentless aortic porcine xenograft valve.
abstract: BACKGROUND
  The advantageous design of the Cryolife-O'Brien stentless porcine aortic valve permits specific quick, easy, supravalvular implantation using single layer continuous 3-0 polypropylene suture. The advantages, contraindications, and implantation errors to avoid are detailed. The use of this valve for aortic valve replacement in the elderly population has been directed to proving its efficacy and establishing its grounds for durability while maintaining all of the advantages of a stentless tissue valve.
  
  
  METHODS
  From December 1992 to September 1998, this valve was used in 240 patients (mean age 73 years: 15% > 80 years), 45% receiving associated coronary artery grafting (2.4 grafts per patient). Left ventricular (LV) myomectomy was necessary in 12% of patients. Detailed postoperative follow-up (100%) analysis included 650 serial echocardiographic studies.
  
  
  RESULTS
  The 30-day mortality was low at 1.2% (3 deaths of 240 elderly patients). Ten patients had late mortality (1.5 months to 5 years), all nonvalve related. No structural failure and one only explant for endocarditis have occurred. Echocardiographic analyses have shown low mean transvalvular gradients in relationship to time (8.18 mmHg at 18 months) and to valve size (8.52 mmHg for a 23-mm host aortic annulus). Incompetence has been zero or a trace in 97% of the patients at 21/2 years. No patient over the 6 years shows valve deterioration.
  
  
  CONCLUSIONS
  Six years of experience with this stentless valve in 240 elderly patients has revealed the many advantages of this safe, composite, and truly stentless device that is assembled without the need for Dacron support. Excellent sustained hemodynamics with low gradients, minimal regurgitation, and a good effective orifice have been coupled with low immediate mortality, no intrinsic valve failure, and one explant for endocarditis. Marked LV regression and minimal late valve-related complications confirm the safety and advantages of this stentless valve.
authors.affiliation: The Department of Cardiac Surgery, The Prince Charles Hospital, Brisbane, Australia. obrienmf@health.qld.gov.au
authors.forename: M F
authors.initials: MF
authors.lastname: O'Brien
authors.forename: M A
authors.initials: MA
authors.lastname: Gardner
authors.forename: R B
authors.initials: RB
authors.lastname: Garlick
authors.forename: M B
authors.initials: MB
authors.lastname: Davison
authors.forename: H L
authors.initials: HL
authors.lastname: Thomson
authors.forename: D J
authors.initials: DJ
authors.lastname: Burstow
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001021:Aortic Valve / Q000000981:diagnostic imaging / Q000601:surgery; D001705:Bioprosthesis; D002302:Cardiac Output; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000295:instrumentation* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D013536:Suture Techniques; D013552:Swine; D014183:Transplantation, Heterologous